Globe Life
GL
$171.08
-7.02%
Globe Life Inc. is an insurance holding company that provides life and supplemental health insurance products and annuities to a broad customer base in the United States. As a well-established player in the life insurance industry, the company differentiates itself through a diversified product portfolio and a focus on middle-income markets. The current investor narrative centers on the company's strong financial performance, with recent quarterly results showing accelerating revenue growth and robust profitability, while analysts maintain a generally bullish consensus on the stock.…
GL
Globe Life
$171.08
GL 12-Month Price Forecast
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Globe Life's 12-month outlook, with a consensus price target around $191.27 and implied upside of +11.8% versus the current price.
Average Target
$191.27
0 analysts
Implied Upside
+11.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$150 - $225
Analyst target range
Globe Life is covered by 11 analysts, with a consensus recommendation of 'Buy' (mean rating of 1.91 on a 1-5 scale where 1 is Strong Buy). The average target price is $186.27, implying a modest 0.82% upside from the current price of $184.76. The distribution shows 6 Overweight/Buy ratings, 4 Hold/In Line, and 1 Sell, leaning bullish but with some caution. The target range spans from $150.00 (low) to $215.00 (high), representing a 43% spread between the lowest and highest estimates. The high target of $215.00 assumes continued growth acceleration and margin expansion, while the low target of $150.00 prices in potential headwinds such as regulatory changes or competitive pressure. Recent ratings from Piper Sandler, Evercore, and Keefe Bruyette & Woods have been reaffirmed at Overweight/Outperform, indicating sustained analyst confidence. The relatively wide spread suggests uncertainty about the pace of future growth, but the overall bullish consensus supports a positive outlook.
Bulls vs Bears: GL Investment Factors
Globe Life presents a compelling value proposition with a trailing P/E of 9.78x, a 56% discount to the industry average, and accelerating revenue growth of 5.35% YoY. Profitability is strong, with gross margins improving to 49.37% and net margins of 17.35%. However, the stock's 51.94% rally over the past year has brought it near the average analyst target of $186.27, limiting near-term upside. The bull case is supported by deep value, robust cash flow, and low volatility (beta 0.47), while the bear case hinges on limited upside to targets and potential regulatory headwinds. The key tension is whether the market will re-rate Globe Life closer to industry multiples (22x P/E) or if the current discount persists due to growth concerns. Overall, the evidence leans bullish given the valuation gap and fundamental strength.
Bullish
- Deep Value with 56% P/E Discount: Globe Life trades at a trailing P/E of 9.78x, a 56% discount to the industry average of 22x, despite superior profitability (net margin 19.4% vs. industry ~10%). This suggests significant upside if the market re-rates the stock closer to peers.
- Accelerating Revenue Growth: Q1 2026 revenue grew 5.35% YoY to $1.56B, accelerating from 2.95% in Q4 2025. The multi-quarter trend shows consistent expansion, driven by strong Life ($853M) and Health ($417M) segments.
- Strong Profitability and Margins: Gross margin improved to 49.37% in Q1 2026 from 31.06% a year ago, while operating margin rose to 23.60% from 21.35%. Net margin of 17.35% is robust for the insurance industry.
- Solid Balance Sheet and Cash Flow: Debt-to-equity is a conservative 0.44, current ratio is 9.66, and trailing twelve-month free cash flow is $1.23B. The company funds share repurchases ($240M in Q1) without external financing.
Bearish
- Limited Upside to Analyst Target: The average analyst target of $186.27 implies only 0.82% upside from the current price of $184.76. With the stock near its 52-week high, near-term gains may be capped.
- Forward P/E Expansion Suggests Caution: The forward P/E of 11.12x is higher than the trailing 9.78x, indicating the market expects earnings growth to slow. This multiple compression could limit valuation upside.
- Regulatory and Competitive Risks: As a life insurer, Globe Life faces regulatory scrutiny on policy terms and reserve requirements. The industry is competitive, and any adverse regulatory changes could pressure margins.
- High Valuation Relative to History: The current P/E of 9.78x is near the high end of its 5-year range (7.3x–15.2x). While still a discount to peers, the stock has already re-rated significantly from its 52-week low of $120.05.
GL Technical Analysis
Globe Life is in a sustained uptrend, with the stock price up 51.94% over the past year, significantly outperforming the S&P 500's 18.35% gain. The current price of $184.76 sits at 96.5% of its 52-week range ($120.05–$191.55), indicating the stock is near its highs and reflecting strong momentum. This positioning suggests the market is pricing in continued positive sentiment, though it also raises the risk of a pullback if catalysts fail to materialize. Short-term momentum is accelerating, with the stock gaining 7.89% in the past month and 21.66% over the past three months, both well above the S&P 500's respective returns of 0.31% and 4.67%. The 1-month relative strength of 7.58% confirms that Globe Life is outpacing the broader market. This short-term strength aligns with the longer-term uptrend, indicating no divergence and supporting a bullish outlook. The 52-week high of $191.55 serves as key resistance, while the 52-week low of $120.05 provides support. A breakout above $191.55 would signal further upside, while a breakdown below $120.05 would be a bearish reversal. The stock's beta of 0.47 indicates it is significantly less volatile than the market, making it a lower-risk holding within a portfolio.
Beta
—
—
Max Drawdown
-11.0%
Largest decline past year
52-Week Range
$123-$192
Price range past year
Annual Return
+37.1%
Cumulative gain past year
| Period | GL Return | S&P 500 |
|---|---|---|
| 1m | -2.6% | +0.6% |
| 3m | +12.1% | +3.4% |
| 6m | +25.3% | +7.1% |
| 1y | +37.1% | +16.4% |
| ytd | +23.6% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
GL Fundamental Analysis
Globe Life's revenue trajectory is accelerating, with Q1 2026 revenue of $1.56 billion, up 5.35% year-over-year from $1.48 billion in Q1 2025. This marks an improvement from the 2.95% YoY growth seen in Q4 2025, driven by strong performance in both the Life segment ($853 million) and Health segment ($417 million). The multi-quarter trend shows consistent growth, with revenue rising from $1.46 billion in Q4 2024 to $1.56 billion in Q1 2026, reinforcing the investment case for steady expansion. The company is highly profitable, with Q1 2026 net income of $270.5 million and a gross margin of 49.37%, up significantly from 31.06% in Q1 2025. Operating margin improved to 23.60% from 21.35% a year earlier, reflecting effective cost management and operating leverage. Net margin of 17.35% is strong for the insurance industry, indicating efficient underwriting and expense control. Globe Life maintains a solid balance sheet with a debt-to-equity ratio of 0.44 and a current ratio of 9.66, indicating ample liquidity. Free cash flow for Q1 2026 was $396 million, up from $420 million in Q1 2025, and the trailing twelve-month free cash flow stands at $1.23 billion. The company generates sufficient cash to fund operations and share repurchases ($240 million in Q1 2026) without relying on external financing, and its ROE of 19.43% reflects strong shareholder value creation.
Quarterly Revenue
$1.6B
2026-03
Revenue YoY Growth
+5.3%
YoY Comparison
Gross Margin
49.4%
Latest Quarter
Free Cash Flow
$1.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is GL Overvalued?
Since Globe Life has positive net income, we lead with the P/E ratio. The trailing P/E is 9.78x, while the forward P/E is 11.12x, implying the market expects earnings growth to moderate slightly. The gap between trailing and forward P/E suggests that while earnings are expected to grow, the multiple is contracting, possibly due to higher interest rates or normalization of underwriting margins. Compared to the industry average P/E of 22x (estimated), Globe Life trades at a 56% discount, which is striking given its superior profitability (net margin of 19.4% vs. industry average of ~10%). This discount may reflect concerns about regulatory risks or slower growth, but it also suggests potential upside if the company continues to deliver strong results. Historically, Globe Life's trailing P/E of 9.78x is near the low end of its 5-year range (7.3x–15.2x), indicating the stock is undervalued relative to its own history. The current multiple is below the median of ~11x, suggesting that the market is pricing in conservative expectations, which could present a buying opportunity if fundamentals remain robust.
PE
9.8x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 7x~15x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.7x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Globe Life's debt-to-equity ratio of 0.44 is manageable, but the company carries $34M in quarterly interest expense, which could pressure earnings if rates rise. The net margin of 17.35% is strong, but any deterioration in underwriting discipline or claims experience could compress margins. Free cash flow of $1.23B TTM provides a cushion, but the payout ratio of 7.4% leaves room for dividend growth, though it remains modest. Revenue concentration in life and health insurance exposes the company to demographic and morbidity trends.
Market & Competitive Risks: The stock's beta of 0.47 indicates low market correlation, but its 56% P/E discount to the industry suggests the market already prices in risks. The forward P/E of 11.12x implies expected earnings deceleration, and if growth disappoints, the multiple could contract further. Competitive pressures from larger insurers and fintech disruptors could erode market share. Regulatory changes, such as reserve requirements or policyholder protections, could increase costs. The stock's 51.94% one-year gain may lead to profit-taking, especially if macro conditions worsen.
Worst-Case Scenario: A severe recession could increase policy lapses and claims, pressuring earnings. If the stock reverts to its 52-week low of $120.05, an investor would face a 35% loss from the current price of $184.76. This scenario could be triggered by a regulatory crackdown, a sharp rise in interest rates hurting investment income, or a major competitive disruption. The analyst low target of $150.00 implies an 18.8% downside, which is a more moderate but still significant risk.